Radioligand Therapy for Lung Cancer

Recruiting in Palo Alto (17 mi)

Yusuf Menda | University of Iowa Health ...

Overseen byYusuf Menda, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Yusuf Menda

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing a new radiation treatment for lung cancer patients who have not responded well to previous treatments. The treatment uses a drug to deliver radiation directly to the cancer cells, aiming to kill them more effectively.

Eligibility Criteria

This trial is for patients with atypical carcinoid lung lesions who've tried or declined other treatments. They must have a lesion ≥2 cm that's positive for CXCR4, can consent independently, and have good liver and kidney function. People with recent major surgery, other recent therapies, pregnant or breastfeeding women, those not using birth control, or with uncontrolled illnesses are excluded.

Inclusion Criteria

I can make my own medical decisions.

My liver tests are within the required limits.

I have a tumor larger than 2 cm that is positive for CXCR4.

+3 more

Exclusion Criteria

I have not received antibody therapy in the last 21 days.

Breastfeeding

Another investigational agent within 4 weeks of consent

+7 more

Participant Groups

The study tests a new alpha-radiation treatment called Lead-212 labelled Pentixather on patients who've had previous treatments for lung carcinoid tumors. It also uses Lead-203 Pentixather SPECT/CT imaging to identify suitable lesions before treatment.

1Treatment groups

Experimental Treatment

Group I: 212-Lead PentixatherExperimental Treatment2 Interventions

Single intravenous infusion of Pentixather radiolabeled with Lead-212. Administered activity to participant is calculated from bone marrow and renal radiation constraints. Treatment is administered in 2 cycles with 6 weeks between the cycles.